Table 5.

Models to assess effects of Serum TMA on Coronary Plaque Parameters in HIV-Infected Subjects

Table 5a.
	Calcium Score (n=146) (R²=0.08; P=0.002)		Total Plaque Segments (#)(n=139) (R²=0.16; P=<0.0001)		Calcified Plaque Segments (#)(n=139) (R²=0.08; P=0.004)		Calcium Volume of Plaque (n=138) (R²=0.08; P=0.003)		Calcium Mass of Plaque (n=138) (R²=0.08; P=0.004)
	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value
Variables
Serum TMA	25.7192	0.008	0.9643	0.005	0.1895	0.02	21.0937	0.01	5.7989	0.007
FRS	2.8206	0.01	0.1718	<0.0001	0.0266	0.009	2.6245	0.01	0.5439	0.04

Table 5b
	Calcium Score (n=123) (R²=0.08; P=0.02)		Total Plaque Segments (#)(n=118) (R²=0.15; P=0.0003)		Calcified Plaque Segments (#)(n=119) (R²=0.08; P=0.02)		Calcium Volume of Plaque (n=117) (R²=0.09; P=0.02)		Calcium Mass of Plaque (n=117) (R²=0.08; P=0.03)
	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value
Variables
Serum TMA	22.9497	0.04	0.8232	0.03	0.1720	0.07	18.2025	0.06	5.2065	0.03
FRS	3.2799	0.02	0.1605	0.0008	0.0293	0.02	3.1836	0.01	0.6456	0.04
LPS	36.0131	0.76	4.9143	0.21	0.6241	0.53	8.0591	0.94	6.7358	0.80

R² represents the coefficient of determination and the proportion of variance explained by the model. P value represents significance by the whole model ANOVA test.

Abbreviations: FRS, Framingham Risk Score; TMA, trimethylamine; LPS, lipopolysaccharide.